We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.82%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$640M
AUM Growth
+$42M
Cap. Flow
+$22.9M
Cap. Flow %
3.57%
Top 10 Hldgs %
39.6%
Holding
108
New
27
Increased
17
Reduced
24
Closed
21

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$8.95M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.93M
3
SHLT
SHL Telemedicine Ltd American Depositary Shares
SHLT
+$7.92M
4
NVMI
Nova
NVMI
+$7.16M
5
TSEM icon
Tower Semiconductor
TSEM
+$6.92M

Top Sells

Rank Stock Value
1
NTR icon
Nutrien
NTR
+$10.7M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$8.87M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$8.02M
4
LLY icon
Eli Lilly
LLY
+$6.71M
5
MSFT icon
Microsoft
MSFT
+$6.37M

Sector Composition

Rank Sector Weight
1 Healthcare 57.28%
2 Technology 9.65%
3 Consumer Discretionary 2.53%
4 Utilities 0.59%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
51
DELISTED
Kezar Life Sciences
KZR
$4.87M 0.76%
198,823
+10,000
+5% +$260K
RCKT icon
52
Rocket Pharmaceuticals
RCKT
$340M
$4.69M 0.73%
236,000
– –
GRCL
53
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$4.68M 0.73%
1,228,665
-1,131,915
-48% -$3.17M
XBI icon
54
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$4.16M 0.65%
+50,000
New +$4.18M
PTCT icon
55
PTC Therapeutics
PTCT
$5.68B
$4.07M 0.64%
100,100
-59,000
-37% -$2.89M
ATXS
56
DELISTED
Astria Therapeutics
ATXS
$3.92M 0.61%
471,018
+50,000
+12% +$577K
ARGX icon
57
PUT
argenx
ARGX
$54.6B
$3.9M 0.61%
+10,000
New +$3.93M
QCOM icon
58
Qualcomm
QCOM
$155B
$3.81M 0.59%
+32,000
New +$3.68M
ENLT icon
59
Enlight Renewable Energy
ENLT
$11.8B
$3.76M 0.59%
211,586
-239,278
-53% -$4.24M
GSK icon
60
GSK
GSK
$104B
$3.56M 0.56%
+100,000
New +$3.59M
TVTX icon
61
Travere Therapeutics
TVTX
$5.2B
$3.28M 0.51%
213,462
+25,962
+14% +$472K
NICE icon
62
CALL
Nice
NICE
$5.79B
$3.1M 0.48%
+15,000
New +$3.09M
GILD icon
63
Gilead Sciences
GILD
$162B
$3.08M 0.48%
+40,000
New +$3.19M
ETNB
64
DELISTED
89bio
ETNB
$2.56M 0.4%
+135,000
New +$2.37M
ACLX
65
DELISTED
Arcellx
ACLX
$2.45M 0.38%
77,488
-90,000
-54% -$3.44M
RZLT icon
66
Rezolute
RZLT
$454M
$2.29M 0.36%
1,155,897
– –
RNAC icon
67
Cartesian Therapeutics
RNAC
$229M
$2.28M 0.36%
67,950
-9,550
-12% -$342K
BBIO icon
68
CALL
BridgeBio Pharma
BBIO
$15.7B
$2.24M 0.35%
130,000
-70,000
-35% -$1.05M
AMLX icon
69
Amylyx Pharmaceuticals
AMLX
$2.26B
$2.16M 0.34%
+100,000
New +$2.7M
ALPN
70
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.06M 0.32%
200,000
– –
HOWL icon
71
Werewolf Therapeutics
HOWL
$17.2M
$1.91M 0.3%
626,810
– –
ALT icon
72
Altimmune
ALT
$552M
$1.76M 0.28%
500,000
+200,000
+67% +$898K
QURE icon
73
uniQure
QURE
$3.03B
$1.7M 0.27%
148,734
+86,734
+140% +$1.64M
VERA icon
74
Vera Therapeutics
VERA
$2.3B
$1.69M 0.26%
+105,000
New +$948K
RIGL icon
75
Rigel Pharmaceuticals
RIGL
$681M
$1.58M 0.25%
122,813
-65,072
-35% -$880K
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2023 Portfolio in Review

As of Q2 2023, Sphera Funds Management held 108 positions worth $640M, up 7% from $598M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Sphera Funds Management deployed $22.9M of net new capital in Q2 2023, opening 27 new positions and adding to 17 existing holdings. Its largest new stake was Praxis Precision Medicines: 584,289 shares worth $10.1M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 60% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $8.02M trimmed.

  • Sphera Funds Management's largest Q2 2023 buy was Praxis Precision Medicines: 584,289 shares worth $10.1M.
  • Sphera Funds Management added most to Amazon in Q2 2023, an estimated $4.41M increase.
  • Sphera Funds Management's biggest Q2 2023 reduction was Teva Pharmaceuticals, cutting an estimated $8.02M.
  • Sphera Funds Management fully exited Nutrien in Q2 2023, selling an estimated $10.7M.
  • Sphera Funds Management's ten largest holdings make up 40% of its $640M portfolio in Q2 2023.
  • Sphera Funds Management opened 27 new positions and closed 21 in Q2 2023.
  • Sphera Funds Management's portfolio value rose 7% quarter-over-quarter to $640M.

Based on Sphera Funds Management's 13F filing for Q2 2023, filed 14 Aug 2023.